Aethlon Medical (NASDAQ:AEMD) Issues Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Aethlon Medical (NASDAQ:AEMD) released its quarterly earnings data on Thursday. The medical equipment provider reported ($2.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.44), Zacks reports.

Aethlon Medical Stock Performance

Shares of AEMD traded down $0.11 during mid-day trading on Thursday, hitting $1.98. 41,600 shares of the company were exchanged, compared to its average volume of 61,669. The stock has a market cap of $1.92 million, a price-to-earnings ratio of -0.09 and a beta of 1.60. Aethlon Medical has a 1-year low of $1.92 and a 1-year high of $53.60. The company has a 50 day moving average of $2.79 and a 200-day moving average of $6.37.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $560.00.

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.